SCHEMBL5330655

SCHEMBL5330655

N=C(N)c1ccc(C(=O)Oc2ccccc2)cc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 1/20 0.66
PRSS1 P07477 6/20 0.63
TMPRSS15 P98073 5/20 0.63
ACR P10323 1/20 0.63
F2 P00734 2/20 0.54
F10 P00742 1/20 0.54
F12 P00748 1/20 0.54
F7 P08709 1/20 0.54
F3 P13726 1/20 0.54
PKM P14618 1/20 0.54
BLM P54132 1/20 0.52
WDR5 P61964 1/20 0.52
NSD2 O96028 1/20 0.51
MAPT P10636 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
KMT2A Q03164 2/20 0.50
PRSS2 P07478 2/20 0.50
PRSS3 P35030 2/20 0.50
MEN1 O00255 1/20 0.50
C1S P09871 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7744358 0.95 PARP10 (0.74) PARP10PRSS1TMPRSS15ACRF2
Hydrochloric Acid SCHEMBL3402436 0.93 PARP10 (0.72) PARP10PRSS1TMPRSS15ACRF2
SCHEMBL20008705 0.86 PLAU (0.61) PARP10PRSS1TMPRSS15ACRF2
SCHEMBL70034 0.86 PARP10 (0.70) PARP10PRSS1TMPRSS15ACRF2
SCHEMBL11272755 0.85 PARP10 (0.89) PARP10PRSS1TMPRSS15ACRF2
SCHEMBL9342118 0.84 PRSS1 (0.64) PARP10PRSS1TMPRSS15F2F10
Carbamic Acid Phenyl Ester SCHEMBL10553901 0.83 F10 (0.61) PARP10PRSS1TMPRSS15F2F10
SCHEMBL10492899 0.82 PARP10 (0.53) PARP10PRSS1TMPRSS15F2F10
SCHEMBL10890871 0.82 PRSS1 (0.72) PARP10PRSS1ACRF2MAPT
SCHEMBL10891811 0.82 PRSS1 (0.65) PARP10PRSS1TMPRSS15ACRF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007039151-A1 BLOCKERS OF TRANSFORMING GROWTH FACTOR BETA AND ITS RECEPTORS FOR THE TREATMENT OF INFECTIOUS DISEASES Universität Zürich (CH) 2007-04-12 WO claimed
US-20180085366-A1 OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE ELYSIUM THERAPEUTICS, INC. 2018-03-29 US disclosed
US-20150275306-A1 METHODS AND MEANS FOR PREDICTING RESISTANCE TO ANTI-CANCER TREATMENT AGENDIA N.V. (NL) 2015-10-01 US disclosed
WO-2007039151-A1 BLOCKERS OF TRANSFORMING GROWTH FACTOR BETA AND ITS RECEPTORS FOR THE TREATMENT OF INFECTIOUS DISEASES Universität Zürich (CH) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180085366-A1 OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE OPRM1, OPRK1, OPRD1 PARP10 3466/4885PRSS1 952/4885TMPRSS15 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.